

according to the Globally Harmonized System

Vaniprevir Formulation

Version 6.1	Revision Date: 29.09.2023		S Number: 790-00022	Date of last issue: 04.04.2023 Date of first issue: 27.10.2014
1. PRODU	JCT AND COMPANY ID	ENT	IFICATION	
Prod	Product name		Vaniprevir Form	ulation
Man	ufacturer or supplier's o	deta	ils	
Com	pany	:	MSD	
Addr	ess	:	Briahnager - Off Wagholi - Pune -	Pune Nagar Road - India 412 207
Telep	phone	:	+1-908-740-400	0
Eme	rgency telephone numbe	r :	+1-908-423-600	0
E-ma	ail address	:	EHSDATASTEW	/ARD@msd.com
Reco	ommended use of the c	hem	ical and restriction	ons on use
	ommended use rictions on use	:	Pharmaceutical Not applicable	

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification Specific target organ toxicity - repeated exposure (Oral)	:	Category 2 (gallbladder, Liver)
Short-term (acute) aquatic hazard	:	Category 3
GHS label elements		
Hazard pictograms	:	
Signal word	:	Warning
Hazard statements	:	H373 May cause damage to organs (gallbladder, Liver) through prolonged or repeated exposure if swallowed. H402 Harmful to aquatic life.
Precautionary statements	:	Prevention:

according to the Globally Harmonized System



Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.1	29.09.2023	25790-00022	Date of first issue: 27.10.2014

P260 Do not breathe dust. P273 Avoid release to the environment.

Response:

P319 Get medical help if you feel unwell.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture	:	Mixture	

Components

Chemical name	CAS-No.	Concentration (% w/w)
Glycerides, C8-10	85409-09-2	>= 50 - < 70
Vaniprevir	923590-37-8	>= 10 - < 20

4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap. Get medical attention if symptoms occur.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and	:	May cause damage to organs through prolonged or repeated exposure if swallowed.
delayed		Contact with dust can cause mechanical irritation or drying of the skin.
Protection of first-aiders	:	Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray



according to the Globally Harmonized System

Vaniprevir Formulation

Version 6.1	Revision Date: 29.09.2023		9S Number: 790-00022	Date of last issue: 04.04.2023 Date of first issue: 27.10.2014
media	fic hazards during fire-	:	concentrations, and potential dust exp	CO2) dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a
Hazar ucts	dous combustion prod-	:	Carbon oxides	
Specil ods	fic extinguishing meth-	:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do
	al protective equipment	:	Evacuate area. In the event of fire	e, wear self-contained breathing apparatus. ective equipment.
6. ACCIDE	NTAL RELEASE MEA	SUF	RES	
tive eo	nal precautions, protec- quipment and emer- procedures	:	Follow safe handl	ective equipment. ing advice (see section 7) and personal pro- recommendations (see section 8).
Enviro	onmental precautions	:	Retain and dispos	akage or spillage if safe to do so. se of contaminated wash water. should be advised if significant spillages
	ods and materials for nment and cleaning up	:	tainer for disposal Avoid dispersal of with compressed Dust deposits sho es, as these may leased into the att Local or national posal of this mate employed in the of mine which regula Sections 13 and 1	dust in the air (i.e., clearing dust surfaces

7. HANDLING AND STORAGE

Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.



according to the Globally Harmonized System

Vaniprevir Formulation

Version 6.1	Revision Date: 29.09.2023	SDS Number: 25790-00022	Date of last issue: 04.04.2023 Date of first issue: 27.10.2014
Advid	I/Total ventilation ce on safe handling litions for safe storage	: Do not breath Do not swallo Avoid contact Avoid prolong Handle in acc practice, base sessment Minimize dus Keep contain Keep away fr Take precaut Take care to environment.	W.
	rials to avoid	Store in acco	rdance with the particular national regulations. with the following product types:

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis	
Vaniprevir	923590-37-8	TWA	300 µg/m3	Internal	
Engineering measures :	Minimize work Apply measur Ensure that du dust collectors signed in a ma	place exposure es to prevent du ust-handling syst s, vessels, and p anner to prevent		st ducts, i) are de- nto the work	
Personal protective equipmen	t				
Respiratory protection :	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Particulates type			•	
Filter type : Hand protection					
Material :	Chemical-resi	stant gloves			
Remarks :	on the concen stance and sp determined fo applications, v	tration and quar ecific to place of r the product. Ch ve recommend c	ds against chemicals htity of the hazardous work. Breakthrough hange gloves often! F clarifying the resistance ed protective gloves	sub- time is not for special ce to	



according to the Globally Harmonized System

Vaniprevir Formulation

Version 6.1	Revision Date: 29.09.2023	SDS Number: 25790-00022	Date of last issue: 04.04.2023 Date of first issue: 27.10.2014
		glove manuface end of workda	cturer. Wash hands before breaks and at the
Eye protection		: Wear the follo Safety goggle	wing personal protective equipment: s
Skin and body protection		, , , ,	e washed after contact.
Hygiene measures		flushing system place. When using d	chemical is likely during typical use, provide eye ms and safety showers close to the working o not eat, drink or smoke. inated clothing before re-use.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Colour	:	tan
Odour	:	odourless
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Density	:	1 g/cm ³
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n- octanol/water	:	No data available



according to the Globally Harmonized System

Vaniprevir Formulation

Version 6.1	Revision Date: 29.09.2023	SDS Number: 25790-00022	Date of last issue: 04.04.2023 Date of first issue: 27.10.2014		
Auto	-ignition temperature	: No data ava	ailable		
Deco	mposition temperature	: No data available			
Visco Vi	osity iscosity, dynamic	: No data ava	ailable		
Vi	iscosity, kinematic	: No data available			
Explo	osive properties	: Not explosiv	ve		
Oxidi	zing properties	: The substance or mixture is not classified as oxidizing.			
Mole	cular weight	: No data ava	ailable		
Partie	cle size	: No data ava	ailable		
10. STAB	ILITY AND REACTIVIT	ŕ			

Reactivity Chemical stability Possibility of hazardous reac- tions	: :	Not classified as a reactivity hazard. Stable under normal conditions. May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials Hazardous decomposition products	:	Oxidizing agents No hazardous decomposition products are known.
'		

11. TOXICOLOGICAL INFORMATION

Information on likely routes of	:	Inhalation
exposure		Skin contact
		Ingestion
		Eye contact

Acute toxicity

Not classified based on available information.

Components:

Glycerides, C8-10: Acute oral toxicity	_D50 (Rat): > 5,000 mg/kg Method: OECD Test Guideline 401 Remarks: Based on data from simi	
Acute inhalation toxicity	_D50 (Rat): > 1.86 mg/l Exposure time: 6 h Fest atmosphere: dust/mist Remarks: Based on data from simi	lar materials



according to the Globally Harmonized System

Vaniprevir Formulation

/ersion .1	Revision Date: 29.09.2023	SDS Number: 25790-00022	Date of last issue: 04.04.2023 Date of first issue: 27.10.2014
Acute	e dermal toxicity	Assessmen toxicity	> 2,000 mg/kg CD Test Guideline 402 t: The substance or mixture has no acute dermal ased on data from similar materials
Vanip	previr:		
Acute oral toxicity		: LD50 (Rat): Remarks: N icity tests.	> 750 mg/kg o adverse effect has been observed in acute tox-
		(0 /	> 300 mg/kg o adverse effect has been observed in acute tox-
			se): > 2,000 mg/kg o mortality observed at this dose.
Skin	corrosion/irritation		

Not classified based on available information.

Components:

Glycerides, C8-10:

Species :	Rabbit
Method :	OECD Test Guideline 404
Result :	No skin irritation
Remarks :	Based on data from similar materials

Vaniprevir:

Species	:	Rabbit
Result	:	No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Glycerides, C8-10:

Species Method Result Remarks	-	Rabbit OECD Test Guideline 405 No eye irritation Based on data from similar materials
Vaniprevir:		

Species	:	Bovine cornea
Method	:	Bovine cornea (BCOP)
Result	:	Mild eye irritation

according to the Globally Harmonized System



Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.1	29.09.2023	25790-00022	Date of first issue: 27.10.2014

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Glycerides, C8-10:

Test Type	:	Buehler Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Method	:	OECD Test Guideline 406
Result	:	negative
Remarks	:	Based on data from similar materials

Vaniprevir:

Test Type	:	Local lymph node assay (LLNA)
Species	:	Mouse
Result	:	negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Glycerides, C8-10:	
Genotoxicity in vitro :	Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative Remarks: Based on data from similar materials
	Test Type: Chromosome aberration test in vitro Method: OECD Test Guideline 473 Result: negative Remarks: Based on data from similar materials
	Test Type: In vitro mammalian cell gene mutation test Method: OECD Test Guideline 476 Result: negative Remarks: Based on data from similar materials
Vaniprevir:	
Genotoxicity in vitro :	Test Type: Chromosomal aberration Test system: Chinese hamster ovary cells Result: negative
	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: Alkaline elution assay



according to the Globally Harmonized System

Vaniprevir Formulation

ersion 1	Revision Date: 29.09.2023	SDS Number: 25790-00022	Date of last issue: 04.04.2023 Date of first issue: 27.10.2014
		Test system: Result: negati	rat hepatocytes ive
Genot	oxicity in vivo	: Test Type: Mi Species: Mou Application Ro Result: negati	oute: Oral
Carci	nogenicity		
Not cla	assified based on ava	ilable information.	
Comp	oonents:		
Vanip	revir:		
	es ation Route y duration	: Rat, male and : Oral : 104 Weeks	
Result	t	: >= 120 mg/kg : negative	body weight
	es ation Route y duration	: Mouse : Oral : 6 Months : >= 300 mg/kg : 75 mg/kg bod	
Result Targe	t t Organs	: negative : gallbladder	, noight
Repro	oductive toxicity		
Not cla	assified based on ava	ilable information.	
<u>Comp</u>	oonents:		
Glyce	rides, C8-10:		
Effect	s on fertility	reproduction/o Species: Rat Application Ro Method: OEC Result: negati	ombined repeated dose toxicity study with the developmental toxicity screening test oute: Ingestion D Test Guideline 422 ive sed on data from similar materials
Effects ment	s on foetal develop-	reproduction/o Species: Rat Application Ro Method: OEC Result: negati	ombined repeated dose toxicity study with the developmental toxicity screening test oute: Ingestion D Test Guideline 422 we sed on data from similar materials
Vanip	revir:		
-	s on fertility		rtility/early embryonic development male and female



according to the Globally Harmonized System

Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.1	29.09.2023	25790-00022	Date of first issue: 27.10.2014
Effects	s on foetal develop-	Result: No effect : Test Type: Deve Species: Rat, fer Application Route General Toxicity Developmental T Symptoms: No s Result: negative Test Type: Devel Species: Rabbit, Application Route General Toxicity Developmental T weight	 Parent: NOAEL: >= 250 mg/kg body weight s on fertility lopment nale e: Oral Maternal: NOAEL: 120 mg/kg body weight Toxicity: LOAEC F1: 180 mg/kg body weight pecific developmental abnormalities lopment female

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (gallbladder, Liver) through prolonged or repeated exposure if swallowed.

Components:

Vaniprevir:

Exposure routes	: Ingestion
Target Organs	: gallbladder, Liver
Assessment	: May cause damage to organs through prolonged or repeated
	exposure.

Repeated dose toxicity

Components:

NOAEL

LOAEL

Application Route

Glycerides, C8-10:

Species	:	Rat
NOAEL	:	>= 1,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	28 Days
Method	:	OECD Test Guideline 407
Remarks	:	Based on data from similar materials
Vaniprevir:		
Species	:	Rat

:	Oral	

: 120 mg/kg

: 360 mg/kg

according to the Globally Harmonized System



Vaniprevir Formulation

Version 6.1	Revision Date: 29.09.2023	SDS Number: 25790-00022	Date of last issue: 04.04.2023 Date of first issue: 27.10.2014
Targ Spec NOA LOA Appl Expo Targ	NEL .	: 6 Months : Liver : Dog : 15 mg/kg : 30 mg/kg : Oral : 9 Months : Liver, gallbladd : Gastrointestina	
Expo	EL	: Mouse : 150 mg/kg : 300 mg/kg : Oral : 90 d : Liver, Kidney, C ach	Gastrointestinal tract, Heart, gallbladder, Stom-

Aspiration toxicity

Not classified based on available information.

:

Experience with human exposure

Components:


Vaniprevir:

Ingestion

Symptoms: stomach discomfort, Diarrhoea, Nausea, Headache

12. ECOLOGICAL INFORMATION

Ecotoxicity		
Components:		
Glycerides, C8-10:		
Toxicity to fish	:	LL50 (Danio rerio (zebra fish)): > 10 - 100 mg/l Exposure time: 96 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 202 Remarks: Based on data from similar materials
Toxicity to algae/aquatic plants	:	NOEC (Desmodesmus subspicatus (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials





Vaniprevir Formulation

Version 6.1	Revision Date: 29.09.2023		0S Number: 790-00022	Date of last issue: 04.04.2023 Date of first issue: 27.10.2014
			mg/l Exposure time: 72 Test substance: V Method: OECD Te	Vater Accommodated Fraction
Vanip	previr:			
	ty to daphnia and other ic invertebrates	:	Exposure time: 48 Method: OECD Te	
			LC50 (Americamy Exposure time: 96 Method: US-EPA Remarks: No toxio	3 h
Toxici plants	ty to algae/aquatic	:	mg/l Exposure time: 72 Method: OECD Te	
			mg/l Exposure time: 72 Method: OECD To	
Toxici	ty to microorganisms	:	EC50: > 1,000 mg Exposure time: 3 Test Type: Respir Method: OECD Te	h ation inhibition
			NOEC: 1,000 mg/ Exposure time: 3 Test Type: Respir Method: OECD To	h ation inhibition
Persis	stence and degradabil	ity		
Comp	oonents:			
-	e rides, C8-10: gradability	:	Result: Readily bi Remarks: Based o	odegradable. on data from similar materials
Vanip Biode	revir: gradability	:	Result: not rapidly Method: OECD To	



according to the Globally Harmonized System

Vaniprevir Formulation

Version 6.1	Revision Date: 29.09.2023	SDS Number: 25790-00022	Date of last issue: 04.04.2023 Date of first issue: 27.10.2014
Bioad	cumulative potentia	I	
Com	ponents:		
Partiti	erides, C8-10: ion coefficient: n- ol/water	: log Pow: < 4	
Partiti	previr: ion coefficient: n- ol/water	: log Pow: 4.12	
	lity in soil ata available		
	r adverse effects ata available		
13. DISPO	SAL CONSIDERATIO	ONS	
-	osal methods e from residues	: Do not dispose	of waste into sewer.

dling site for recycling or disposal.	waste from residues		Do not dispose of waste into sewer.
dling site for recycling or disposal.			Dispose of in accordance with local regulations.
	Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal.
			If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture



according to the Globally Harmonized System

Vaniprevir Formulation

Version 6.1	Revision Date: 29.09.2023		DS Number: 5790-00022	Date of last issue: 04.04.2023 Date of first issue: 27.10.2014
The d AICS DSL	• •	oduo : :	ct are reported in not determined not determined	the following inventories:
IECS	С	:	not determined	
16. OTHE	R INFORMATION			
Revis	sion Date	:	29.09.2023	
Furth	ner information			
	ces of key data used to ile the Safety Data t	:		data, data from raw material SDSs, OECD arch results and European Chemicals Agen- ropa.eu/
Date	format	:	dd.mm.yyyy	

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for

according to the Globally Harmonized System



Vaniprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
6.1	29.09.2023	25790-00022	Date of first issue: 27.10.2014

safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN